Skip to search formSkip to main contentSkip to account menu

valganciclovir

Known as: VGCV, L-valine, ester with ganciclovir, ganciclovir L-valyl ester 
A synthetic prodrug of ganciclovir, a nucleoside analogue of 2'-deoxyguanosine, with antiviral activity. After phosphorylation, valganciclovir is… 
National Institutes of Health

Related topics

Related topics

15 relations
AIDS-Related Opportunistic InfectionsAnemiaCytomegalovirus InfectionsCytomegalovirus Retinitis

Broader (2)

Antiviral AgentsGanciclovir

Narrower (3)

CymevalValcyteValganciclovir hydrochloride

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
Prospective study on CMV-reactivations under preemptive strategy in CMV-seropositive adult liver transplant recipients.
2011
2011
Artesunate is ineffective in controlling valganciclovir-resistant cytomegalovirus infection.
To the Editor—Cytomegalovirus (CMV) disease is a common pathogen and represents a difficult clinical problem in transplant… 
Review
2011
Review
2011
Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation
Martin JM, Danziger‐Isakov LA. Cytomegalovirus risk, prevention, and management in pediatric solid organ transplantation.
Pediatr… 
2010
2010
Choice of induction regimens on the risk of cytomegalovirus infection in donor‐positive and recipient‐negative kidney transplant recipients
F.L. Luan, M. Samaniego, M. Kommareddi, J.M. Park, A.O. Ojo. Choice of induction regimens on the risk of cytomegalovirus… 
2010
2010
Viral-associated trichodysplasia of immunosuppression: report of a pediatric patient with response to oral valganciclovir.
BACKGROUND Viral-associated trichodysplasia of immunosuppression is an increasingly recognized entity characterized by follicular… 
2008
2008
Prospective follow-up of primary CMV infections after 6 months of valganciclovir prophylaxis in renal transplant recipients.
BACKGROUND The occurrence and clinical course of late primary CMV infections developing after valganciclovir prophylaxis in high… 
2006
2006
Epstein‐Barr virus (EBV) serology for predicting distant metastases in a white juvenile patient with nasopharyngeal carcinoma and no clinical response to EBV lytic induction therapy
We describe a case of a 16‐year‐old white girl with Epstein‐Barr virus (EBV)‐positive nasopharyngeal carcinoma (NPC). 
2004
2004
Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas–kidney, and pancreas transplantation
Abstract:  Cytomegalovirus, seen in more than 50% of solid organ transplant recipients, is responsible for numerous direct and… 
Highly Cited
2004
Highly Cited
2004
Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant Recipients
Background. Cytomegalovirus (CMV) D+/R− solid-organ transplant (SOT) recipients carry increased risk of developing CMV disease… 
2004
2004
Oral valganciclovir in children: single dose pharmacokinetics in a six-year-old girl
We report a pharmacokinetic study in a 6-year-old girl with congenital human immunodeficiency virus type 1 and cytomegalovirus… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)